Item 8.01. Other Events.
On January 28, 2021, CASI Pharmaceuticals, Inc. (the "Company") announced that
its partner, BioInvent International AB, released positive interim results from
its Phase I/IIa trial that suggests that novel anti-FcyRIIB antibody BI-1206
restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients. The
Company's press release is attached to this Current Report on Form 8-K as
Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number Description
99.1 Press Release of CASI Pharmaceuticals, Inc., dated January 28,
2021
104 Inline XBRL for the cover page of this Current Report on Form
8-K
© Edgar Online, source Glimpses